How to cite: Davis BJ. “Radiation in the Treatment of Oligometastatic Nodal Disease.” Grand Rounds in Urology. October 23, 2025. Accessed Apr 2026. https://grandroundsinurology.com/radiation-in-the-treatment-of-oligometastatic-nodal-disease/
Summary
Brian J. Davis, MD, PhD, FABS, Professor of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, reviews the role of radiation therapy in the management of oligometastatic nodal prostate cancer in the modern positron emission tomography (PET) imaging era. Dr. Davis frames oligometastatic disease as a biologically distinct state in which a limited metastatic burden may be amenable to durable disease control through targeted local and regional therapy.
He begins with historical context, including the seminal oligometastasis framework proposed by Hellman and Weichselbaum, and contrasts metastatic patterns observed in the pre-PET era with those detected using contemporary molecular imaging. Dr. Davis highlights that with PET-based detection, more than 80 percent of first recurrences after definitive local therapy occur in pelvic or para-aortic lymph nodes rather than bone or visceral sites.
Anatomic distinctions between regional N1 and distant M1a nodal disease are reviewed in detail, with emphasis on pelvic, common iliac, presacral, peri-rectal, and para-aortic nodal stations. Sentinel lymph node mapping studies demonstrate that traditional radiation fields may omit clinically relevant nodal regions, particularly the presacral and common iliac nodes.
Clinical evidence supporting elective nodal radiation therapy is reviewed across multiple disease states, including clinically node-positive disease, pathologically node-positive disease after prostatectomy, and nodal recurrence following prior radiotherapy. Retrospective and population-based studies consistently demonstrate improved cancer-specific and overall survival when local or regional radiotherapy is added to systemic therapy.
Dr. Davis presents institutional data using PET-guided salvage extended nodal radiation therapy, showing low in-field recurrence rates and favorable biochemical control with acceptable toxicity. Moderate hypofractionation regimens using intensity-modulated radiation therapy (IMRT) or proton therapy are shown to produce low rates of acute and late genitourinary and gastrointestinal toxicity.
Randomized data comparing stereotactic body radiotherapy to elective nodal radiation are discussed, emphasizing that broader nodal coverage improves metastasis-free survival by addressing occult disease beyond PET-avid targets. Dr. Davis advocates for regional nodal irradiation as a preferred strategy in nodal oligometastatic prostate cancer.
About the 28th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Brian J. Davis, MD, PhD, FABS, is a Professor of Radiation Oncology at Mayo Clinic in Rochester, Minnesota. Dr. Davis also serves as a consultant for the Department of Radiation Oncology and the Department of Physiology & Biomedical Engineering at Mayo Clinic. He specializes in genitourinary cancer, and his research interests include prostate cancer, proton therapy, intensity-modulated radiation therapy, external beam radiotherapy, and brachytherapy.
